Valion Bio Secures FDA-Precedent for Entolimod™ Development Funding and Collaboration

On May 5, 2026, Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) announced an important advancement in its mission to develop Entolimod™, a medical countermeasure designed for Acute Radiation Syndrome (ARS). The company has officially received the first study protocol from the National Institute of Allergy and Infectious Diseases (NIAID), which fully funds their Biologics License Application (BLA)-enabling in vivo studies. This unprecedented support from NIAID aligns with the Agency’s historical approval pathways, significantly advancing Valion Bio’s chances for clinical success.

Overview of NIAID Support

The agreement with NIAID is a pivotal milestone, with a funding potential of up to $7 million directed towards essential studies that are required for filing Valion Bio's BLA. NIAID’s involvement not only provides financial resources but also invaluable regulatory knowledge to assist Valion Bio in navigating the FDA submission process. This collaboration reflects a growing governmental commitment to supporting innovative approaches in medical countermeasures, especially those addressing urgent needs like ARS.

The study protocol that Valion Bio has received mirrors a previously employed design that was accepted by the FDA for an earlier ARS countermeasure. This alignment provides a considerable advantage, as having a previously accepted design serves to de-risk the study outcomes dramatically. The studies will be executed at the Armed Forces Radiobiology Research Institute (AFRRI), a leading facility for ARS countermeasure assessment.

Targeting an Urgent Medical Need

The initial study centers on Partial-Body Irradiation Gastrointestinal Acute Radiation Syndrome (PBI-GI-ARS). Valion Bio’s aim is to evaluate the efficacy of Entolimod™ for preserving critical gastrointestinal tissue after radiation exposure. Currently, no approved treatments exist within the U.S. Strategic National Stockpile that can effectively address gastrointestinal damage in such scenarios. The potential implications of this research are significant, given that partial-body irradiation often manifests in real-life situations involving nuclear incidents or radiation exposure from dirty bombs.

The unique aspect of the PBI-GI-ARS study is that it could establish Entolimod™ as a singular countermeasure capable of offering both hematopoietic support and gastrointestinal protection following lethal radiation exposure. This broad-spectrum efficacy is currently unmet by other existing stockpiled agents.

Advantages of NIAID Partnership

Michael K. Handley, CEO of Valion Bio, emphasized the importance of this partnership, noting, “This is not a grant application waiting for a decision — the federal government is actively funding the science, providing an FDA-precedent protocol, and committing to walk our submission into the agency alongside us.” This active engagement offers a distinct risk-reward profile that private funding cannot typically match, creating opportunities that could lead to significant advancements in the field of radiation countermeasures.

Moreover, this funding allows Valion Bio to refocus its previously allocated capital of approximately $7 million towards other therapeutic developments, such as Entolasta™, an innovative second-generation molecule targeting a wider array of medical applications. The continued momentum in Valion Bio’s research pipeline enhances the company's ability to build a multifaceted portfolio of therapeutics, offering potential solutions across multiple platforms.

Clinical Path and Future Outlook

Entolimod™, developed as a TLR5 agonist, has already achieved significant milestones, including Fast Track and Orphan Drug designations from the FDA for ARS. The substance has undergone extensive evaluation in primates and has been administered to around 300 human subjects since its inception, making it a promising candidate for further development. The anticipated in vivo studies funded by NIAID will cover all necessary testing on the critical path to BLA submission.

In conclusion, Valion Bio’s collaboration with NIAID not only marks a landmark event in the journey toward novel therapeutic solutions for radiation exposure but also creates a robust foundation for future medical advancements that could save countless lives in critical situations. The ongoing progress and growing governmental involvement highlight a dedicated response to unmet medical needs in disaster preparedness and emergency medicine.

For insights into Valion Bio’s innovative treatments and updates on their clinical pipeline, visit Valion Bio's official website.